Research ArticleAccepted Article
Open Access
Secukinumab in US Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
Tien Nguyen, Melvin Churchill, Robert Levin, Guillermo Valenzuela, Joseph F. Merola, Alexis Ogdie, Ana-Maria Orbai, Jose U. Scher, Arthur Kavanaugh, Farid Kianifard, Chauncy Rollins, Renato Calheiros and Olivier Chambenoit
The Journal of Rheumatology April 2022, jrheum.210912; DOI: https://doi.org/10.3899/jrheum.210912
Tien Nguyen
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Melvin Churchill
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Robert Levin
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Guillermo Valenzuela
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Joseph F. Merola
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Alexis Ogdie
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Ana-Maria Orbai
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Jose U. Scher
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Arthur Kavanaugh
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Farid Kianifard
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Chauncy Rollins
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Renato Calheiros
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Olivier Chambenoit
Funding: This work was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Initials, surnames, appointments, and highest academic degrees: T. Nguyen, MD, First OC Dermatology, Irvine, CA, USA; M. Churchill, MD, Arthritis Center of Nebraska, Lincoln, NE, USA; R. Levin, MD, Clinical Research of West Florida, Inc, Clearwater, FL, USA, and University of South Florida, Tampa, FL, USA; G. Valenzuela, MD, Integral Rheumatology & Immunology Specialists, Plantation, FL, USA; J. F. Merola, MD, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; A. Ogdie, MD, MSCE, Department of Medicine/Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; A. -M. Orbai, MD, MHS, Division of Rheumatology, Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; J. U. Scher, MD, Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, USA; A. Kavanaugh, MD, Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA; F. Kianifard, PhD, C. Rollins, MS, R. Calheiros, MD, O. Chambenoit, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of interest: T. Nguyen has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Janssen, Novartis, Pfizer, Sanofi Regeneron, and UCB; as an investigator for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Lilly, GSK, Merck, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie, Almirall, Amgen, Celgene, Lilly, Novartis, Pfizer, Sanofi Regeneron, and Sun Pharma. M. Churchill has served as a clinical investigator for Novartis. R. Levin has served as a consultant for Gilead and Myriad Genetics; has conducted clinical trials for AbbVie, Amgen, Lilly, Pfizer, Sanofi, and UCB; and is a speaker for AbbVie, Bristol Myers Squibb, and Sanofi. G. Valenzuela has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi Regeneron, and UCB; and as MLCKDT Investigator for Bristol Myers Squibb, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi Regeneron. J. F. Merola has served as a consultant for AbbVie, Biogen, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Samumed, Sanofi Regeneron, Science 37, and UCB; as an investigator for Biogen, Incyte, Novartis, Pfizer, and Sanofi Regeneron; and as a speaker for AbbVie. A. Ogdie has served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Corrona, Lilly, Novartis, and Pfizer; has received research funding from Novartis and Pfizer to the University of Pennsylvania and from Amgen to Forward/NDB; has served as a speaker for AbbVie, Amgen, and Celgene; and her husband has received royalties from Novartis related to a patent. A.-M. Orbai has received research grants to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis; and consulting fees from Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. J. U. Scher has received grant support from Novartis, Janssen and Pfizer and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer and UCB. A. Kavanaugh has served as a consultant for and conducted clinical research sponsored by Novartis. F. Kianifard, C. Rollins, R. Calheiros, and O. Chambenoit are employees and stockholders of Novartis Pharmaceuticals Corporation. Address correspondence to: Tien Q. Nguyen, MD, First OC Dermatology, 17305 Von Karman Avenue, Suite 107, Irvine, CA 92614; phone: (949) 679-9997; fax: (949) 679-9933; email: tiennguyenmd82@gmail.com. Statement of ethics and consent: The study was approved by a central institutional review board (Chespeake IRB, now Advarra; IRB#00000971) and by the institutional review board or independent ethics committee at each participating institution, and was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent before starting any study-related procedures.
Data supplements
210912 Video Abstract
Files in this Data Supplement:
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Secukinumab in US Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
Tien Nguyen, Melvin Churchill, Robert Levin, Guillermo Valenzuela, Joseph F. Merola, Alexis Ogdie, Ana-Maria Orbai, Jose U. Scher, Arthur Kavanaugh, Farid Kianifard, Chauncy Rollins, Renato Calheiros, Olivier Chambenoit
The Journal of Rheumatology Apr 2022, jrheum.210912; DOI: 10.3899/jrheum.210912
Accepted manuscript
Secukinumab in US Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
Tien Nguyen, Melvin Churchill, Robert Levin, Guillermo Valenzuela, Joseph F. Merola, Alexis Ogdie, Ana-Maria Orbai, Jose U. Scher, Arthur Kavanaugh, Farid Kianifard, Chauncy Rollins, Renato Calheiros, Olivier Chambenoit
The Journal of Rheumatology Apr 2022, jrheum.210912; DOI: 10.3899/jrheum.210912